Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

541. Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007

Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007 Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007 Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007 Smith KJ, Hsu HE, Roberts MS, Kramer MK, Orchard TJ, Piatt GA, Seidel MC (...) risk of type 2 diabetes and cardiovascular disease. The authors concluded that the modified DPP delivered in community and primary care settings was cost-effective and a sound investment. The methods were generally good and satisfactorily reported, as were the data sources and the results. The authors' conclusions appear to be appropriate. Type of economic evaluation Cost-utility analysis Study objective This study examined the cost-effectiveness of a community-based screening and modified Diabetes

NHS Economic Evaluation Database.2010

542. Behavioral counseling to promote physical activity and a healthful diet to prevent cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force

Behavioral counseling to promote physical activity and a healthful diet to prevent cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force Behavioral counseling to promote physical activity and a healthful diet to prevent cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force Behavioral counseling to promote physical activity and a healthful diet to prevent cardiovascular disease in adults: a systematic review (...) To assess the effect of dietary or physical activity counselling on health outcomes, intermediate cardiovascular disease-related outcomes, behavioural outcomes and harms associated with these interventions. Searching MEDLINE, PsycINFO and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for the period January 2001 to January 2010. Search terms were provided. References lists of relevant publications and reviews were searched. Input from experts was sought. There appeared

DARE.2010

543. Systematic review: Intensive glucose control in type 2 diabetes reduces cardiovascular disease, but not cardiovascular or all-cause mortality, and increases risk of severe hypoglycaemia

Systematic review: Intensive glucose control in type 2 diabetes reduces cardiovascular disease, but not cardiovascular or all-cause mortality, and increases risk of severe hypoglycaemia Intensive glucose control in type 2 diabetes reduces cardiovascular disease, but not cardiovascular or all-cause mortality, and increases risk of severe hypoglycaemia | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Intensive glucose control in type 2 diabetes reduces cardiovascular disease, but not cardiovascular or all

Evidence-Based Nursing (Requires free registration)2010

544. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis

Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM Record Status This is a critical abstract of an economic evaluation that meets (...) the population's sodium intake by the same amount as it did in the UK and the data were from UK published reports. The sodium tax strategy was assumed to be similar to tobacco taxes and the data were based on a published study of cigarette tax. The link between reduced sodium intake and the risk of cardiac events was estimated from relevant published studies. Published meta-analyses on blood pressure and cardiovascular disease were used to calibrate the data. Background population risk data were from

NHS Economic Evaluation Database.2010

545. Community programs for the prevention of cardiovascular disease: a systematic review

Community programs for the prevention of cardiovascular disease: a systematic review Community programs for the prevention of cardiovascular disease: a systematic review Community programs for the prevention of cardiovascular disease: a systematic review Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, Hyde C CRD summary This review concluded that community programmes aimed at reducing cardiovascular disease risk in people without evidence of cardiovascular disease resulted (...) in generally favourable changes in overall cardiovascular disease risk. Because of problems related to the quality of included data, applicability to current conditions and methods of data synthesis, the authors' conclusions should be treated with caution. Authors' objectives To assess the effectiveness of community programmes for preventing cardiovascular disease. Searching MEDLINE, EMBASE, CINAHL, PsycINFO, HMIC, ASSIA and The Cochrane Library were searched from January 1970 to July 2008. Search terms

DARE.2010

546. Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease

Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease Hamon M, Fau G, Nee G, Ehtisham J, Morello R, Hamon M CRD summary This review (...) concluded that stress perfusion cardiovascular magnetic resonance was highly sensitive for detection of coronary artery disease and its specificity was moderate. Given limitations of the synthesis and the statistical and clinical variability across the studies, the reliability of the pooled results is uncertain and the conclusions should be treated with caution. Authors' objectives To determine the accuracy of stress perfusion cardiovascular magnetic resonance for diagnosis of significant obstructive

DARE.2010

547. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.

Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. Duggal JK, Singh M, Attri N, Singh PP, Ahmed N, Pahwa S, Molnar J, Singh S, Khosla S, Arora R CRD summary This review concluded that niacin therapy was associated with a statistically significant reduction the risk (...) of cardiovascular events in patients with coronary artery disease, but the small decrease in coronary and cardiovascular mortality was not statistically significant. As most of the data came from older trials (1975 to 1990) that may not be as relevant to current practice, the authors' conclusions should be treated with caution. Authors' objectives To evaluate the effect of niacin on cardiovascular outcomes in patients with coronary artery disease. Searching PubMed, EMBASE, CINAHL and the Cochrane Library were

DARE.2010

548. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: a pooled meta-analysis of randomized placebo-controlled clinical trials

Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: a pooled meta-analysis of randomized placebo-controlled clinical trials Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: a pooled meta-analysis of randomized placebo-controlled clinical trials Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: a pooled meta-analysis of randomized placebo-controlled clinical (...) trials comprised patients both with and without previous histories of cardiovascular disease and myocardial infarction. The mean age of patients in included trials ranged from 47 to 64 years; the proportion of men ranged from 63 to 100% of the enrolled population. The fibrate medications given in the trials were gemfibrozil (1200mg/day), bezafibrate (400mg/day) and fenofibrate (200mg/day). The endpoints evaluated were all-cause mortality, cardiac mortality, fatal and non-fatal myocardial infarction

DARE.2010

549. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis Younis N, Williams S, Ammori B, Soran H CRD summary This review concluded that aspirin for primary prevention of cardiovascular events, in people with diabetes, did not reduce (...) than English and unpublished studies were excluded. Study selection Randomised controlled trials (RCTs) were eligible if they included people with diabetes, and compared aspirin to placebo or no aspirin for primary prevention of cardiovascular disease. Studies of mixed primary and secondary prevention were eligible if data for primary prevention was available separately. The outcomes of interest were major cardiovascular events, myocardial infarction, stroke and all-cause mortality. In the included

DARE.2010

550. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome

Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome 19932775 2009 11 25 2010 02 01 2016 11 25 1879-1913 104 11 2009 Dec 01 The American journal of cardiology Am. J. Cardiol. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis (...) Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). 1457-64 10.1016/j.amjcard.2009.07.035 We examined the impact of metabolic syndrome (MS) on coronary stenosis progression and major cardiovascular (CV) events and investigated the mitigating effects of low-density lipoprotein (LDL) cholesterol lowering and LDL cholesterol lowering plus high-density lipoprotein (HDL) cholesterol increasing. This analysis combined individual patient data

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

551. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis.

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. 21109302 2010 12 06 2010 12 16 2015 06 16 1474-547X 376 9756 2010 Dec 04 Lancet (London, England) Lancet Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests (...) in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. 1916-22 10.1016/S0140-6736(10)61272-X Long-term statin treatment reduces the frequency of cardiovascular events, but safety and efficacy in patients with abnormal liver tests is unclear. We assessed whether statin therapy is safe and effective for these patients through post-hoc analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study population. GREACE was a prospective

Lancet2010

552. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. 21115589 2010 11 30 2010 12 13 2017 02 20 1756-1833 341 2010 Nov 29 BMJ (Clinical research ed.) BMJ Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. c6273 10.1136/bmj.c6273 bmj.c6273 To investigate whether dietary supplementation with B vitamins or omega 3 fatty acids, or both, could prevent major cardiovascular events (...) of eicosapentanoic acid and docosahexaenoic acid at a ratio of 2:1) or placebo. Median duration of supplementation was 4.7 years. Major cardiovascular events, defined as a composite of non-fatal myocardial infarction, stroke, or death from cardiovascular disease. Allocation to B vitamins lowered plasma homocysteine concentrations by 19% compared with placebo, but had no significant effects on major vascular events (75 v 82 patients, hazard ratio, 0.90 (95% confidence interval 0.66 to 1.23, P=0.50)). Allocation

BMJ2010 Full Text: Link to full Text with Trip Pro

553. Cardiovascular disease prevention

Cardiovascular disease prevention Cardio Cardiovascular disease pre vascular disease prev vention ention Public health guideline Published: 22 June 2010 nice.org.uk/guidance/ph25 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cardiovascular disease prevention (PH25) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 113Contents Contents Overview 5 Who is it for? 5 Introduction 6 1 Recommendations 7 Recommendations

National Institute for Health and Clinical Excellence - Clinical Guidelines2010

555. Case management to reduce risk of cardiovascular disease in a county health care system

Case management to reduce risk of cardiovascular disease in a county health care system 19933961 2009 11 25 2009 12 08 2017 02 20 1538-3679 169 21 2009 Nov 23 Archives of internal medicine Arch. Intern. Med. Case management to reduce risk of cardiovascular disease in a county health care system. 1988-95 10.1001/archinternmed.2009.381 Case management (CM) is a systematic approach to supplement physician-centered efforts to prevent cardiovascular disease (CVD). Research is limited on its (...) Aged Body Weight California Cardiovascular Diseases ethnology etiology prevention & control Case Management Counseling Diet Female Health Behavior Humans Income Male Middle Aged Minority Groups Nurse's Role Preventive Health Services methods organization & administration Risk Assessment Risk Factors Risk Reduction Behavior Sex Factors NIHMS227921 PMC3000904 2009 11 26 6 0 2009 11 26 6 0 2009 12 16 6 0 ppublish 19933961 169/21/1988 10.1001/archinternmed.2009.381 PMC3000904 NIHMS227921

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

556. Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults

Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults 19682127 2009 10 07 2009 10 28 2016 10 19 1532-5415 57 10 2009 Oct Journal of the American Geriatrics Society J Am Geriatr Soc Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. 1874-80 10.1111/j.1532-5415.2009.02438.x To determine whether older (...) adults with high plasma carboxymethyl-lysine (CML), an advanced glycation end product, are at higher risk of all-cause and cardiovascular disease (CVD) mortality. Prospective cohort study. Population-based sample of adults aged 65 and older residing in Tuscany, Italy. One thousand thirteen adults participating in the Invecchiare in Chianti study. Anthropometric measures, plasma CML, fasting plasma total, high-density and low-density lipoprotein cholesterol, triglycerides, glucose, creatinine

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

557. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses` health study

Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses` health study 19790130 2009 10 14 2009 11 17 2016 11 22 0004-3591 61 10 2009 Oct 15 Arthritis and rheumatism Arthritis Rheum. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. 1396-402 10.1002/art.24537 Systemic lupus erythematosus (SLE) has been associated with an increased risk of cardiovascular disease. However, prospective population-based (...) data addressing this association have been lacking. We conducted a prospective cohort study among 119,332 women participating in the Nurses' Health Study who were free of cardiovascular disease and SLE at baseline in 1976. Incident SLE was confirmed by medical record review. Cardiovascular events included fatal and nonfatal myocardial infarction, stroke, coronary artery bypass grafting, and angioplasty. The relative risk (RR) of cardiovascular events among participants with SLE as compared

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

558. Worksite Opportunities for Wellness (WOW): effects on cardiovascular disease risk factors after 1 year

Worksite Opportunities for Wellness (WOW): effects on cardiovascular disease risk factors after 1 year 19576927 2009 09 28 2010 02 25 2017 02 20 1096-0260 49 2-3 2009 Aug-Sep Preventive medicine Prev Med Worksite Opportunities for Wellness (WOW): effects on cardiovascular disease risk factors after 1 year. 108-14 10.1016/j.ypmed.2009.06.022 To evaluate the effectiveness of a worksite health promotion program on improving cardiovascular disease risk factors. In St Louis, Missouri from 2005 (...) and fat mass were different between worksites. A multi-faceted worksite intervention promoted favorable changes in cardiovascular disease risk factors, but many of the improvements were achieved with worksite health assessments and personalized health reports in the absence of an intervention. Racette Susan B SB Washington University School of Medicine, Campus Box 8502, 4444 Forest Park Avenue, St. Louis, MO 63108-2212, USA. racettes@wustl.edu Deusinger Susan S SS Inman Cindi L CL Burlis Tamara L

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

559. Aspirin for the Prevention of Cardiovascular Disease: Published Comments and Response

Aspirin for the Prevention of Cardiovascular Disease: Published Comments and Response U.S. Preventive Services Task Force: Aspirin for the Prevention of Cardiovascular Disease [Published Comments and Response] Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser. Search | | | | | | | You Are Here: > > > Published Comments & Response Published Comments and Response Aspirin for the Prevention of Cardiovascular Disease First (...) published as Letters to the Editor in Annals of Internal Medicine 151(58):587-88, October 20, 2009. / / TO THE EDITOR: The recently updated U.S. Preventive Services Task Force (USPSTF) guidelines ( ) on aspirin for primary prevention of cardiovascular disease are an ideal example of evidence-based medicine in action. Although we cannot fully explain why aspirin effects differ by sex, the evidence strongly suggests that they do. Now our guidelines, and practices, can reflect that. The concept makes

Publication 3262009

560. Central obesity and cigarette smoking are key determinants of cardiovascular disease deaths in Australia: a public health perspective

Central obesity and cigarette smoking are key determinants of cardiovascular disease deaths in Australia: a public health perspective 19660494 2009 09 28 2010 02 25 2009 09 28 1096-0260 49 2-3 2009 Aug-Sep Preventive medicine Prev Med Central obesity and cigarette smoking are key determinants of cardiovascular disease deaths in Australia: a public health perspective. 153-7 10.1016/j.ypmed.2009.07.019 Our objective is to develop a parsimonious model to predict coronary heart disease (CHD) and (...) cardiovascular disease (CVD) deaths using individual components of the Framingham risk score plus measures of central obesity. 15 year mortality follow-up of 8662 representative Australian adults in the National Heart Foundation Risk Factor Prevalence Survey of 1989, excluding those with a baseline history of heart disease, stroke or diabetes. Measures included blood pressure, fasting lipids, smoking history, body mass index (BMI), waist circumference (WC) and waist to hip ratio (WHR). Multivariable logistic

EvidenceUpdates2009